Drugs / LY2275796
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00903708 | Sep 2006 → Jun 2010 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2005-04-21 | Ionis Pharmaceuticals | Results Multiple Second-Generation Antisense Drugs Effectively Inhibit Tumor Growth and Show Potential as New Anti-Cancer Drugs ionis.com ↗
Further, the drug appeared to be highly effective in animal models of cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2005-04-21 | Ionis Pharmaceuticals | Multiple Second-Generation Antisense Drugs Effectively Inhibit Tumor Growth and Show Potential as New Anti-Cancer Drugs ionis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2275796 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00903708 ↗ |
| Action | Inhibit | “LY2275796 is designed to block the effect of a cancer-promoting gene called eIF-4E (eukaryotic initiation factor 4E).” NCT00903708 ↗ |
| Route | Intravenous | “LY2275796 will be given by an infusion into your vein over 3 days.” NCT00903708 ↗ |
| Target | EIF4E | “LY2275796 is designed to block the effect of a cancer-promoting gene called eIF-4E (eukaryotic initiation factor 4E).” NCT00903708 ↗ |